CHEK2 and prostate carcinoma: These data confirmed a report by Isaacsson Velho and colleagues [209], who found a similar proportion of mutation carriers (21/150; 14%) among unselected prostate cancer patients with an identical proportion of affected genes: BRCA2 (N = 9; 43%), ATM (N = 3; 14%), CHEK2 (N = 3; 14%), and BRCA1 (N = 2; 9%).